Related Experiment Video
Updated: Jul 26, 2026
Survivable Stereotaxic Surgery in Rodents
Published on: October 6, 2008
[Imatinib and beyond-what is important for surgery?]
R Hamacher1, J Falkenhorst1, J Treckmann2
1Innere Klinik (Tumorforschung), Sarkomzentrum am Westdeutschen Tumorzentrum, Universitätsklinik Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Deutschland.
Abstract:
The treatment of gastrointestinal stromal tumors (GIST) has dramatically improved since the introduction of small molecule KIT proto-oncogene receptor tyrosine kinase inhibitors. Nevertheless, the cure of patients is still based on surgical treatment of the primary tumor. The chance of long-term tumor control by tyrosine kinase inhibitors (TKI) even in the metastatic setting also appears to be improved after achieving a surgical complete resection. The decision on which patients will most likely profit from multimodal treatment approaches is increasingly based on complex molecular predictors in addition to clinical factors and also a profound understanding of the biology of GIST that requires discussion in a multidisciplinary, highly experienced treatment team. Novel, more potent inhibitors enable a response to treatment in so far treatment-refractory GIST subtypes, such as the platelet-derived growth factor receptor (PDGFR) D842V mutated GIST subtype and also appear to show treatment benefits even in KIT mutated GIST after the failure of all approved treatments. These treatments are expected to profoundly change treatment algorithms in the near future.
Insights
Gastrointestinal stromal tumors (GIST) treatment has improved with tyrosine kinase inhibitors (TKI). Novel inhibitors offer new hope for refractory GIST subtypes and advanced cases, potentially changing future treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Gastrointestinal Surgery
Background:
- Gastrointestinal stromal tumors (GIST) treatment has advanced significantly with KIT inhibitors.
- Surgical resection of primary tumors remains crucial for curative treatment.
- Tyrosine kinase inhibitors (TKI) show improved long-term tumor control, especially after surgical resection.
Purpose of the Study:
- To review the evolving treatment landscape for GIST.
- To highlight the role of molecular predictors and multidisciplinary teams in GIST management.
- To discuss the impact of novel inhibitors on treatment-refractory GIST subtypes.
Main Methods:
- Review of current literature on GIST treatment strategies.
- Analysis of the efficacy of tyrosine kinase inhibitors (TKI) in various GIST settings.
- Discussion of emerging therapies for specific GIST mutations.
Main Results:
- Introduction of small molecule KIT inhibitors has dramatically improved GIST treatment.
- Surgical complete resection enhances the efficacy of TKI in metastatic GIST.
- Novel potent inhibitors demonstrate efficacy in PDGFR D842V and KIT-mutated GIST, including treatment-refractory cases.
Conclusions:
- Multimodal treatment approaches for GIST require complex molecular predictors and a deep understanding of GIST biology.
- Novel inhibitors are poised to significantly alter GIST treatment algorithms.
- Future GIST management will likely involve personalized therapies based on molecular profiles.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...